We were delighted to have the opportunity to speak with Prof. Marc A Pfeffer (Distinguished Dzau Professor of Medicine, Harvard Medical School, Boston, MA, US) to discuss the PARADISE-MI trial investigating sacubitril/valsartan vs. ramipril in a contemporary enriched AMI population, presented at ACC 2021.
Abstract Title: Prospective ARNI vs. ACE inhibitor trial to DetermIne Superiority in reducing heart failure Events after Myocardial Infarction – PARADISE-MI
Speaker disclosures: Marc A Pfeffer has received consulting fees/honorarium from: Novo Nordisk, AstraZeneca Pharmaceuticals, DalCor, GlaxoSmithKline, Sanofi-Aventis, Boehringer Ingelheim-Lilly, Corvidia, Peerbridge, Novartis; Research/research grants from: Novartis; Other financial benefit: Novartis, DalCor
Support: Interview and filming supported by Touch Medical Media and conducted by Nicola Cartridge
Filmed during a remote video call with Professor Marc A Pfeffer as a highlight of ACC 2021, May 2021.
